News
Pfizer has joined the ranks of companies developing cancer drugs that target both PD-1 and VEGF – one of the hottest drug classes in oncology, via a $6 billion licensing deal with China's 3SBio.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results